AACC uses Cookies to ensure the best website experience. Continuing without changing Cookie settings assumes you consent to our use of cookies on this device. You can change these settings at any time, but that may impair functionality on our websites. Review our cookie and privacy policy

Novel Biomarkers of Kidney Disease: False Dawn or New Horizon? 30th Beckman Conference

Atlanta, Georgia

Tuesday, November 5

Session 1: Biomarkers in Clinical Practice

What is a Biomarker and What Role do Biomarkers Play in Modern Medicine?
Rob Christenson, PhD, University of Maryland, Baltimore, MD
(Slides) (Handouts)

Clinical Practice Modifications and Acute Kidney Injury Biomarkers
Lakhmir Chawla, MD, George Washington University Medical Center, Washington, DC
(Slides) (Handouts)

Overview of Current Biomarkers in Kidney Disease
Joseph Bonventre, MD, PhD, Harvard University Medical School, Boston, MA
(Slides) (Handouts)

Session 2: Chronic Kidney Disease (CKD): Improving the Prediction of Disease Progression

Biomarkers of Diabetic Renal Disease
Andrzej Krolewski, MD, PhD, Joslin Diabetes Center, Boston, MA
(Slides) (Handouts)

The Search for Improved Markers of CKD
Chi-yuan Hsu, MD, University of California – San Francisco
(Slides) (Handouts)

Biomarkers of CKD Progression and Mortality in HIV
Michael Shlipak, MD, University of California – San Francisco
(Slides) (Handouts)

Session 3: Acute Kidney Injury (AKI) Biomarkers: Lessons from Multicenter Studies

Application of Novel Biomarkers in Perioperative AKI
Chirag Parikh, MD, PhD, Yale University , New Haven, CT
(Slides) (Handouts)

Novel Biomarkers in Critically Ill Patients and the Emergency Room
Jay Koyner, MD, University of Chicago, IL
(Slides) (Handouts)

Pediatric Acute Kidney Injury and Application of Biomarkers
Michael Zappitelli, MD, McGill University, Canada
(Slides) (Handouts)

Biomarkers of Long-Term Mortality and CKD After AKI
Steven Coca, DO, Yale University, New Haven, CT
(Slides) (Handouts)

Session 4: Kidney Biomarkers in Other Diseases

Novel Biomarkers Liver Injury and Hepatorenal Syndrome
Arun Sanyal, MD, Virginia Commonwealth University Medical School, Richmond, VA
(Slides) (Handouts)

Congestive Heart Failure and Cardiorenal Syndrome: Is There A Role for Biomarkers?
Wilson Tang, MD, Cleveland Clinic, OH
(Slides) (Handouts)

Using Biomarkers in Management and Prognosis of Contrast-Induced Acute Kidney Injury
Steven Weisbord, MD, University of Pittsburgh Medical Center, PA
(Slides) (Handouts)

Wednesday, November 6

Session 5: Kidney Biomarkers in Transplantation and Prevention of Organ Rejection

Molecular Diagnosis of Rejection in Renal Transplant Biopsies: New Insights into Outcomes
Philip Halloran, MD, PhD, University of Alberta, Canada
(Slides) (Handouts)

Proteomic Discovery of Biomarkers for Diagnosis of Acute and Chronic Outcomes in Renal Allografts
John Arthur, MD, PhD, Medical University of South Carolina, Charleston, SC
(Slides) (Handouts)

Session 6: A Debate - Biomarkers in Acute Kidney Injury Clinical Trials: Are They Ready or Not?

Pro - John Kellum, MD, University of Pittsburgh Medical Center, PA
(Slides) (Handouts)

Con - Sushrut Waikar, MD, Brigham and Women's Hospital, Boston, MA
(Slides) (Handouts)

Session 7: Experimental Methods

Multiple Reaction Monitoring to Validate Urinary Biomarkers
Jennifer Van Eyk, PhD, Johns Hopkins University Medical Institutions, Baltimore, MD
(Slides) (Handouts)

High Resolution Mass Spectrometry in Discovery
Michael Merchant, PhD, University of Louisville School of Medicine, KY
(Slides) (Handouts)

Micro RNAs New Frontiers in Kidney Disease
Vishal Vaidya, PhD, Harvard University School of Medicine, Boston, MA
(Slides) (Handouts)

Metabolomics and Other Non-Proteomic Methods
Susan Sumner, PhD, Research Triangle institute, NC
(Slides) (Handouts)

Session 8: Statistics and Study Design

Use of Acute Kidney Injury Biomarkers in Clinical Trials - Design Considerations
Amit Garg, MD, PhD, McMaster University, Ontario, Canada
(Slides) (Handouts)

Assessing Biomarker Performance and Sample Size Calculations of Biomarkers
Heather Thiessen-Philbrook, MS, London Health Sciences Centre, Canada
(Slides) (Handouts)

Reclassification Metrics and the Use of Biomarkers as Surrogates
Michael Pencina, PhD, Duke Clinical Research Institute, Durham, NC
(Slides) (Handouts)

Session 9: Measurement Questions

Laboratory Method Harmonization and Standardization: What a Nephrologist Needs to Know
Greg Miller, PhD, Virginia Commonwealth University Medical School, Richmond, VA
(Slides) (Handouts)

Getting a New Marker Approved by the Food and Drug Administration
Courtney Lias, PhD, Food and Drug Administration, Rockville, MD
(Slides) (Handouts)